Stocktoria

Benitec Biopharma Inc. BNTC

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2012-07-11

Benitec Biopharma Inc. financials (annual)

Revenue
$12.2M $102000 $59000 $73000 $75000 $0 20192020202120222023202420252026
Net income
$2.6M -$8.3M -$13.9M -$18.2M -$19.6M -$21.8M -$37.9M -$45.5M 20192020202120222023202420252026
Free cash flow
$4.4M -$7.6M -$13.1M -$15.9M -$18.0M -$19.6M -$23.6M -$16.6M 20192020202120222023202420252026

Bars are annual figures from 2019 to 2026; red bars are negative (a loss or cash outflow).

MetricFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue——$0$75,000$73,000$59,000$102,000$12.2M
R&D expense$23.4M$18.3M$15.6M$12.8M$11.3M$7.0M$3.0M$4.6M
Operating income-$51.2M-$41.8M-$22.5M-$19.1M-$17.9M-$13.6M-$8.3M$2.6M
Income tax$0———————
Net income-$45.5M-$37.9M-$21.8M-$19.6M-$18.2M-$13.9M-$8.3M$2.6M
EPS (diluted)$-0.98$-1.05$-1.22$-14.12$-37.88$-3.23——
Operating cash flow-$16.5M-$23.6M-$19.4M-$18.0M-$15.9M-$12.8M-$7.5M$4.8M
Free cash flow-$16.6M-$23.6M-$19.6M-$18.0M-$15.9M-$13.1M-$7.6M$4.4M
Cash & equivalents$180.0M$97.7M$50.9M$2.5M$4.1M$19.8M$9.8M$15.7M
Total assets$182.6M$99.6M$52.2M$4.5M$6.0M$21.4M$11.6M$19.2M
Total liabilities$5.6M$2.3M$5.0M$4.3M$3.1M$1.4M$1.3M$2.6M
Shareholders' equity$177.0M$97.3M$47.2M$202,000$2.9M$20.0M$10.2M$16.6M

Growth · year-over-year

MetricFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue growth——-100.0%+2.7%+23.7%-42.2%-99.2%—
Net income growth——————-417.1%—
Free cash flow growth——————-274.0%—

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.